Middle East And Africa Lymphangioleiomyomatosis Lam Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 5.66 Million |
 시장 규모(예측 연도) |
USD 7.19 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>중동 및 아프리카 림프항원평활근종증(LAM) 시장, 질병 유형(결절성 경화증 복합형 Lam, 산발성 Lam), 유형(진단, 치료), 합병증(기흉, 유미흉, 신장 종양, 흉막 삼출액, 부기 및 체액 축적, 기타), 투여 경로(경구, 비경구), 최종 사용자(병원, 전문 진료소, 진단 센터, 재택 의료 및 기타), 유통 채널(직접 입찰, 병원 약국, 소매 약국, 온라인 약국 및 기타), 국가(남아프리카, 사우디 아라비아, UAE, 이스라엘, 이집트 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 중동 및 아프리카 림프관평활근종증(LAM) 시장
중동 및 아프리카 림프관평활근종증(LAM) 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 3.3%의 CAGR로 성장하고 있으며 2020년 566만 달러에서 2028년까지 719만 달러에 도달할 것으로 예상된다고 분석했습니다. 당뇨병 발병률 증가와 림프관평활근종증(LAM)에 대한 새로운 기술 발전의 성장은 예측 기간 동안 시장 수요를 촉진하는 주요 동인이 될 가능성이 높습니다.
림프관평활근종증(LAM)은 폐계 , 신장계, 림프계에 영향을 미치는 희귀한 낭포성 만성 폐 질환 입니다 . 림프계는 림프액과 면역 세포를 몸 전체로 운반하는 역할을 하는 혈관의 조정된 네트워크로 구성되어 있습니다. LAM은 여성에게 발생합니다. 20~40세의 여성이 LAM 진단을 받습니다. 결절성 경화증이 있는 여성의 약 30%가 LAM에 걸리기 쉽습니다. 이는 종종 결절성 경화증 복합체(TSC), TSC 1 유전자의 돌연변이로 인해 발생합니다. 고립성 또는 산발성 LAM은 LAM이 단독으로 발생하는 것을 말합니다.
만성 낭포성 폐질환의 유병률 증가, 여성의 혈관근지방종과 결절성 경화증의 증가, 임상 시험의 증가는 림프관평활근종증(LAM) 시장 성장의 길을 닦습니다. 게다가 신흥 경제권에서 림프관평활근종증(LAM)의 성장 잠재력과 제품(진단 기계와 제네릭 의약품)의 증가는 림프관평활근종증(LAM) 시장 성장을 뒷받침합니다. 그러나 LAM 치료 비용의 증가, 부과된 엄격한 규제, 개발도상국에서 치료를 받을 수 없다는 것은 시장 성장을 방해할 수 있는 제약입니다. 사용된 재료의 불일치는 시장 성장을 방해할 수 있는 제약입니다.
The Middle East and Africa lymphangioleiomyomatosis (LAM) market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Lymphangioleiomyomatosis (LAM) Market Scope and Market Size
Middle East and Africa lymphangioleiomyomatosis (LAM) market is segmented on the basis of disease type, type, complications, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the Middle East and Africa lymphangioleiomyomatosis (LAM) market is segmented into tuberous sclerosis complex lam and sporadic lam. In 2021, the tuberous sclerosis complex lam segment is dominating the Middle East and Africa lymphangioleiomyomatosis (LAM) market due to the increased prevalence of lam in patients with tuberous sclerosis are predicted to dominate the market.
- On the basis of type, the Middle East and Africa lymphangioleiomyomatosis (LAM) market is segmented into diagnosis and treatment. In 2021 the treatment segment is dominating the Middle East and Africa lymphangioleiomyomatosis (LAM) market owing to the rise in the number of cases and availability of diagnostic and lung transplants.
- On the basis of complications, the Middle East and Africa lymphangioleiomyomatosis (LAM) market is segmented into pneumothorax, chylothorax, kidney tumor, pleural effusions, swelling & fluid build-up and others. In 2021, the pneumothorax segment is expected to dominate the Middle East and Africa lymphangioleiomyomatosis (LAM) market due to the increased prevalence of female patients suffering from chronic lung diseases in Middle East and lack of treatment in Africa are predicted to dominate the market.
- On the basis of route of administration, the Middle East and Africa lymphangioleiomyomatosis (LAM) market is segmented into oral, parenteral. In 2021, the oral segment is expected to dominate the Middle East and Africa lymphangioleiomyomatosis (LAM) market due to the ease of absorption, and the medication being cost effective are predicted to dominate the market.
- 최종 사용자를 기준으로 중동 및 아프리카 림프관평활근종증(LAM) 시장은 병원, 전문 클리닉, 진단 센터, 홈 헬스케어 및 기타로 세분화됩니다. 2021년에는 림프관평활근종증 치료에 대한 필요성이 증가하고 제네릭 의약품의 저렴성이 시장을 지배할 것으로 예상되어 병원 부문이 중동 및 아프리카 림프관평활근종증(LAM) 시장을 지배할 것으로 예상됩니다.
- 유통 채널을 기준으로 중동 및 아프리카 림프관평활근종증(LAM) 시장은 직접 입찰, 병원 약국, 소매 약국, 온라인 약국 등으로 세분화됩니다. 2021년에는 시롤리무스 약물 접근성 증가, 일일 처방 횟수 급증, 아프리카에서 진단 약물 및 기관지 확장제 공급을 위한 연락처 수 증가로 인해 직접 입찰 부문이 중동 및 아프리카 림프관평활근종증(LAM) 시장을 지배할 것으로 예상되며, 시장을 지배할 것으로 예상됩니다.
중동 및 아프리카 림프관평활근종증(LAM) 시장 국가 수준 분석
중동 및 아프리카 림프관평활근종증(LAM) 시장이 분석되고 제품 및 서비스, 샘플 유형, 프로세스, 응용 프로그램, 화합물 라이브러리 크기, 최종 사용자 및 유통 채널별로 시장 규모 정보가 제공됩니다.
중동 및 아프리카 림프관평활근종증(LAM) 시장 보고서에서 다루는 국가는 남아프리카공화국 , 사우디아라비아, UAE, 이집트, 이스라엘과 나머지 중동 및 아프리카 국가입니다.
- 중동 및 아프리카 림프관평활근종증(LAM) 시장에서 남아프리카는 2021년에서 2028년까지의 예측 기간 동안 상당한 성장률을 기록할 것으로 예상됩니다. 중동 및 아프리카 국가는 주요 개발도상국 중 하나이며 제약 및 생명공학 분야에서 R&D 활동을 늘리고 아웃소싱 서비스를 확대하는 데 주력하고 있기 때문입니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
신흥 경제권에서의 림프관평활근종증(LAM)의 성장 잠재력과 시장 참여자들의 전략적 이니셔티브는 중동 및 아프리카 림프관평활근종증(LAM) 시장에서 새로운 기회를 창출하고 있습니다.
중동 및 아프리카 림프관평활근종증(LAM) 시장은 또한 림프관평활근종증(LAM) 판매와 림프관평활근종증(LAM) 발전의 영향, 림프관평활근종증(LAM) 시장에 대한 지원과 함께 규제 시나리오의 변화로 특정 산업의 모든 국가 성장에 대한 자세한 시장 분석을 제공합니다. 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 중동 및 아프리카 림프관평활근종증(LAM) 시장 점유율 분석
중동 및 아프리카 림프관평활근종증(LAM) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 포함된 세부 정보입니다. 위에 제공된 데이터 포인트는 림프관평활근종증(LAM) 시장과 관련된 회사의 초점에만 관련됩니다.
아시아 태평양 림프관평활근종증(LAM)을 제공하는 주요 회사로는 Pfizer Inc., Intas Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Novartis AG, Terumo Corporation, Hikma Pharmaceuticals PLC, Care Dx, Morgan Scientific, Taj Pharmaceuticals Limited 등이 있습니다.
DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.
림프관평활근종증(LAM)에 대한 새로운 기술적 발전과 더불어 시장 참여자들의 전략적 이니셔티브는 만성 상처 치료의 격차를 메우고 있습니다.
예를 들어,
- 2021년 5월, Novartis AG와 Molecular Partners는 COVID-19 치료를 위한 ensovibep에 대한 EMPATHY 임상 시험의 시작을 발표했습니다. 실시된 임상 시험은 환자의 시기적절한 치료와 제품 포트폴리오의 개선으로 이어질 것입니다.
협력, 합작사업 및 시장 참여자의 기타 전략은 림프관평활근종증(LAM) 시장에서 회사 시장을 향상시키고 있으며, 이는 기업이 림프관평활근종증(LAM) 시장에 대한 제공 사항을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET INDICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN PREVALENCE OF CHRONIC CYSTIC LUNG DISORDERS
7.1.2 RISE OF ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) IN WOMEN
7.1.3 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 HEALTHCAREREIMBURSEMENTFOR LYMPHANGIOLEIOMYOMATOSIS
7.2 RESTRAINTS
7.2.1 RISE IN COST FOR LYMPHANGIOLEIOMYOMATOSIS (LAM) TREATMENT
7.2.2 AVAILABILITY OF ALTERNATIVES
7.2.3 HIGH COMPLEXITY IN LAM
7.2.4 STRICT REGULATORY FRAMEWORK
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE
7.3.2 RISE IN PRODUCT APPROVALS
7.3.3 USE OF NON-INVASIVE PROCEDURE
7.4 CHALLENGES
7.4.1 SIDE EFFECTS FOUND DURING LAM TREATMENT
7.4.2 PATIENT COMPLIANCE DURING THE TREATMENT OF LAM
8 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.1 ANALYSIS ON IMPACT OF COVID-19 ON LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.2 IMPACT ON PRICE OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.3 IMPACT ON DEMAND OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.4 IMPACT ON SUPPLY CHAIN OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.5 STRATEGIC DECISIONS BY MANUFACTURERS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.6 CONCLUSION
9 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 TUBEROUS SCLEROSIS COMPLEX LAM
9.3 SPORADIC LAM
10 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE
10.1 OVERVIEW
10.2 TREATMENT
10.2.1 MEDICATION
10.2.2 MTOR INHIBITORS
10.2.3 SIROLIMUS/ RAPAMYCIN
10.2.4 EVEROLIMUS
10.2.5 OTHERS
10.2.6 BRONCHODILATORS
10.2.7 ALBUTEROL
10.2.8 SALMETEROL
10.2.9 GLYCOPYRROLATE
10.2.10 OTHERS
10.2.11 OXYGEN THERAPY
10.2.12 LUNG TRANSPLANTATION
10.2.13 BILATERAL LUNG TRANSPLANTATION (BLT)
10.2.14 SINGLE-LUNG TRANSPLANTATION (SLT)
10.3 DIAGNOSIS
10.3.1 IMAGING TEST
10.3.2 CHEST X-RAYS
10.3.3 CHEST CT SCANS
10.3.4 MRI OF ABDOMEN
10.3.5 OTHERS
10.3.6 LUNG FUNCTION TEST
10.3.7 BLOOD TEST (VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D))
10.3.8 LUNG BIOPSY
10.3.9 VIDEO-ASSISTED THORASCOPIC LUNG BIOPSY
10.3.10 TRANSBRONCHIAL LUNG BIOPSY
10.3.11 OTHERS
10.3.12 OTHERS
11 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS
11.1 OVERVIEW
11.2 PNEUMOTHORAX
11.3 PLEURAL EFFUSIONS
11.4 KIDNEY TUMOR
11.5 CHYLOTHORAX
11.6 SWELLING & FLUID BUILD-UP
11.7 OTHERS
12 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLET
12.2.2 CAPSULES
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
13 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 DIAGNOSTIC CENTER
13.5 HOME HEALTHCARE
13.6 OTHERS
14 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACIES
14.4 RETAIL PHARMACIES
14.5 ONLINE PHARMACIES
14.6 OTHERS
15 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION
15.1 OVERVIEW
15.1 MIDDLE EAST AND AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 EGYPT
15.1.5 ISRAEL
15.1.6 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
17 COMPANY PROFILE
17.1 TERUMO CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 CAREDX, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 PFIZER INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 APOTEX INC
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 HIKMA PHARMACEUTICALS PLC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 HERSILL
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HOME OXYGEN COMPANY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 INTAS PHARMACEUTICALS, LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 INOGEN INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 MORGAN SCIENTIFIC
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PULMONE ADVANCED MEDICAL DEVICES
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 PARAGONIX TECHNOLOGIES, INC
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 DR REDDY’S LABORATORIES LTD.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 SANDOR
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD)
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 TRANSMEDICS GROUP INC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 TAJ PHARMACEUTICALS LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 XVIVO
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA TUBEROUS SCLEROSIS COMPLEX LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SPORADIC LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA PLEURAL EFFUSIONS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA KIDNEY TUMOR IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA CHYLOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA SWELLING & FLUID BUILD-UP IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA HOSPITALS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA DIAGNOSTIC CENTER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA HOME HEALTHCARE IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA DIRECT TENDER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 1 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 18 SOUTH AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 19 SOUTH AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 SOUTH AFRICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 SOUTH AFRICA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 SOUTH AFRICA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 SOUTH AFRICA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 24 SOUTH AFRICA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 SOUTH AFRICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 SOUTH AFRICA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 SOUTH AFRICA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 SOUTH AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 29 SOUTH AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 SOUTH AFRICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 SOUTH AFRICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 32 SOUTH AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 SOUTH AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 SAUDI ARABIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 35 SAUDI ARABIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 SAUDI ARABIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 SAUDI ARABIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 38 SAUDI ARABIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 39 SAUDI ARABIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 SAUDI ARABIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 SAUDI ARABIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 SAUDI ARABIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 43 SAUDI ARABIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 SAUDI ARABIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 45 SAUDI ARABIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 46 SAUDI ARABIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 47 SAUDI ARABIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 48 SAUDI ARABIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 49 SAUDI ARABIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 50 U.A.E. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 51 U.A.E. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 U.A.E. TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 U.A.E. MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 U.A.E. MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 U.A.E. BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 U.A.E. LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 U.A.E. DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 U.A.E. IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 U.A.E. LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 U.A.E. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 61 U.A.E. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 U.A.E. ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 63 U.A.E. PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 64 U.A.E. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 65 U.A.E. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 66 EGYPT LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 67 EGYPT LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 EGYPT TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 EGYPT MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 EGYPT MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 EGYPT BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 EGYPT LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 EGYPT DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 EGYPT IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 EGYPT LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 EGYPT LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 77 EGYPT LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 EGYPT ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 EGYPT PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 EGYPT LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 EGYPT LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 ISRAEL LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 83 ISRAEL LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 ISRAEL TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 ISRAEL MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 ISRAEL MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 ISRAEL BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 ISRAEL LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 ISRAEL DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 ISRAEL IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 ISRAEL LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 ISRAEL LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 93 ISRAEL LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 94 ISRAEL ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 ISRAEL PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 ISRAEL LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 97 ISRAEL LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 98 REST OF MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: MIDDLE EAST & AFRICA VS REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: MARKET INDICATION COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC CYSTIC LUNG DISORDER , RISE IN CLINICAL TRIALS AND PRESENCE OF HEALTHCARE REIMBURSEMENT IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKETIN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 DISEASE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
FIGURE 15 PREVALENCE OF CHRONIC PULMONARY (LUNG) CYSTS, WHICH INCREASES WITH AGE
FIGURE 16 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISORDER , HIGHER IN FEMALES
FIGURE 17 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE, 2020
FIGURE 18 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY TYPE, 2020
FIGURE 19 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COMPLICATIONS, 2020
FIGURE 20 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 21 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY END USER, 2020
FIGURE 22 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 23 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 24 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020)
FIGURE 25 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2021 & 2028)
FIGURE 26 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020 & 2028)
FIGURE 27 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 28 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 29 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020)
FIGURE 30 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 31 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 32 MIDDLE EAST AND AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 33 MIDDLE EAST & AFRICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
